98%
921
2 minutes
20
Background: α-Antitrypsin (A1AT) deficiency predisposes patients to pulmonary disease due to inadequate protection against human neutrophil elastase released during inflammatory responses. A1AT deficiency is caused by homozygosity or compound heterozygosity for A1AT variants; individuals with A1AT deficiency most commonly have at least one Z variant allele (c.1096G > A (Glu366Lys)). Null variants that result in complete absence of A1AT in the plasma are much rarer. With one recent exception, all reported A1AT variants are characterized by a single pathogenic variant.
Case: An 8 years old patient from Edmonton, Alberta, Canada, was investigated for A1AT deficiency. His A1AT phenotype was determined to be M (wild type)/Null by isoelectric focusing (IEF) but M/Z by targeted genotyping. Gene sequencing revealed two heterozygous variants: Z and Ile100Asn (c.299 T > A). The Ile100Asn substitution is predicted to disrupt the secondary structure of an α-helix in which it resides and the neighbouring tertiary structure, resulting in intracellular degradation of A1AT prior to hepatocyte secretion.
Methods: Family testing was conducted to verify potential inheritance of an A1AT allele carrying the two mutations in cis, as this arrangement of the mutations would explain "Z" detection by genotyping but not by IEF. Molecular modeling was used to assess the effect of the variants on A1AT structure and stability.
Discussion: Carrier status for a novel variant Null with in cis mutations (c.[299 T > A;1096G > A], p.[(Ileu100Asn;Glu366Lys)]) was confirmed. A sibling was identified as having A1AT deficiency on the basis of compound heterozygosity for two alleles: Null and the common Z allele. A separate pedigree from the Maritimes was subsequently recognized as carrying Null.
Conclusion: In cis mutations such as Null may be more common than previously described due to failure to detect such mutations using historical testing methods. Combined approaches that include gene sequencing and segregation studies allow recognition of rare A1AT variants, including in cis mutations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clinbiochem.2020.02.013 | DOI Listing |
BMC Pulm Med
August 2025
Respire - Instituto para el cuidado respiratorio, Santa Marta, Magdalena, Colombia.
Background: Alpha-1 antitrypsin (AAT) is a medium-sized globular glycoprotein distributed in serum and tissues. In the lungs, it inhibits serine proteases and has anti-inflammatory properties in different types of cells, protecting lung tissue from damage. Mutations in the SERPINA1 gene that codes for AAT are related to asthma and chronic obstructive pulmonary disease.
View Article and Find Full Text PDFAnn Saudi Med
August 2025
From the Department of Medical Sciences II, Faculty of Medicine and Health Sciences, Universiti Sains Islam, Nilai, Negeri Sembilan, Malaysia.
Background: Alpha-1 antitrypsin (A1AT) deficiency has been recognized as an adverse prognostic determinant in severe instances of COVID-19.
Objective: To determine the A1AT phenotypes and levels in individuals at various clinical stages of COVID-19 compared to healthy controls.
Design: Case-control study.
Indian J Clin Biochem
July 2025
Department of Biochemistry, Fergusson College, Pune, India.
COPD has been projected as the fourth leading cause of death globally by 2030. WHO recommends screening of COPD subjects for Alpha-1 Antitrypsin (A1AT) deficiency. Serum A1AT below 20% of normal value indicates A1AT deficiency.
View Article and Find Full Text PDFHum Mutat
July 2025
Pediatric I, Center for Pediatric and Adolescent Medicine, Medical Faculty of Heidelberg, Heidelberg, Germany.
SLC35A1-CDG is a very rare type of congenital disorders of glycosylation (CDG) with only five cases known to date. Here, we review the literature and present new data from a sixth patient carrying the uncharacterized variant c.133A>G; p.
View Article and Find Full Text PDFNat Biotechnol
June 2025
Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Alpha-1 antitrypsin (A1AT) deficiency (AATD) is caused by a mutation in the SERPINA1 gene (PiZ allele), where misfolded A1AT liver accumulation leads to liver damage, and A1AT deficiency in the lungs results in emphysema due to unregulated neutrophil elastase activity. Base editing offers a potential cure for A1AT; however, effective treatment is hindered by the absence of dual-target delivery systems that can target key tissues. We developed Dual Selective ORgan-Targeting lipid nanoparticles (SORT LNPs) to deliver base editors to the liver and lungs.
View Article and Find Full Text PDF